Arecor Therapeutics (AREC) Competitors GBX 49.38 +0.74 (+1.52%) As of 06:39 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock AREC vs. ORPH, REDX, ETX, SBTX, COS, C4XD, DDDD, SAR, TRX, and FUMShould you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), Tissue Regenix Group (TRX), and Futura Medical (FUM). These companies are all part of the "biotechnology" industry. Arecor Therapeutics vs. Its Competitors Open Orphan Redx Pharma e-therapeutics SkinBioTherapeutics Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Sareum Tissue Regenix Group Futura Medical Arecor Therapeutics (LON:AREC) and Open Orphan (LON:ORPH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Is AREC or ORPH more profitable? Open Orphan has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. Open Orphan's return on equity of 0.00% beat Arecor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arecor Therapeutics-176.89% -118.67% -37.31% Open Orphan N/A N/A N/A Does the media refer more to AREC or ORPH? In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score. Company Overall Sentiment Arecor Therapeutics Neutral Open Orphan Neutral Do insiders and institutionals have more ownership in AREC or ORPH? 44.1% of Arecor Therapeutics shares are held by institutional investors. 25.3% of Arecor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has better valuation & earnings, AREC or ORPH? Open Orphan has higher revenue and earnings than Arecor Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArecor Therapeutics£6.04M3.09-£10.68M-£28.30-1.75Open Orphan£34.71M0.00N/AN/AN/A SummaryOpen Orphan beats Arecor Therapeutics on 4 of the 7 factors compared between the two stocks. Get Arecor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AREC vs. The Competition Export to ExcelMetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£18.64M£129.84M£5.53B£3.01BDividend YieldN/A3.74%5.06%5.02%P/E Ratio-1.753.5028.58160.66Price / Sales3.094,168.62372.64293,821.64Price / Cash5.0713.1924.7227.97Price / Book2.9843.018.234.64Net Income-£10.68M-£92.15M£3.19B£5.90B7 Day Performance12.23%1.13%5.46%7.26%1 Month Performance14.84%6.02%9.39%12.68%1 Year Performance-53.42%170.19%30.48%62.03% Arecor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARECArecor TherapeuticsN/AGBX 49.38+1.5%N/A-54.1%£18.64M£6.04M-1.7510News CoverageORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179Positive NewsREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 16.63+0.8%N/A+86.7%£37.98M£1.56M-10.2311COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718K-1.08106SARSareumN/AGBX 21+6.3%N/A-46.1%£26.24MN/A-4.973,211Gap DownTRXTissue Regenix GroupN/AGBX 28.50flatN/A-61.4%£25.69M£31.98M-29.42120FUMFutura MedicalN/AGBX 7.85+5.4%N/A-67.3%£24.47M£8.68M-6.4812Gap Up Related Companies and Tools Related Companies Open Orphan Alternatives Redx Pharma Alternatives e-therapeutics Alternatives SkinBioTherapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Sareum Alternatives Tissue Regenix Group Alternatives Futura Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AREC) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
